MDA and AFM co-sponsored a symposium on neuromuscular gene therapy at the 2012 meeting of the American Society for Gene & Cell Therapy
Overcoming barriers to gene therapy — the delivery of therapeutic genes — to treat neuromuscular diseases was the topic of a symposium jointly sponsored by MDA and the Association Française Contre les Myopathies (French Association Against Myopathies, or AFM) at the 15th annual meeting of the American Society of Gene & Cell Therapy (ASGCT).
Gene therapy researcher and MDA grantee Jerry Mendell discusses autoimmunity to dystrophin protein in Duchenne muscular dystrophy
A January 2011 podcast from Nationwide Children's Hospital in Columbus, Ohio, probes a subject that's been on the minds of many researchers, doctors and families: autoimmunity (self-immunity) in Duchenne muscular dystrophy (DMD).
ALS TDI investigators have found that disrupting part of the immune system slows disease progression in mice with an ALS-like disease
Blocking a key molecular pathway that the body uses to amplify an immune response has been found to delay disease onset and extend survival in mice with a disease that mimics human amyotrophic lateral sclerosis (ALS), say researchers at the MDA-supported ALS Therapy Development Institute (ALS TDI) in Cambridge, Mass.
This article presents reports on research in: Duchenne MD, Becker MD, facioscapulohumeral MD, limb-girdle MD types 2A and 2B, Myioshi myopathy, nemaline myopathy, polymyositis, dermatomyositis, inclusion-body myositis, slow-channel myasthenic syndrome, myasthenia gravis, Lambert-Eaton syndrome and spinal muscular atrophy.